Objective-To determine the impact on final adult height of bone marrow transplantation. Methods-The final height of 28 long term survivors (18 males; 10 females), allografted before or at the onset of puberty, at a median age of 10*8 years (range 6*3 to 14.6) and who did not receive growth hormone (GH) treatment or other growth promoting agents, was evaluated. Median follow up period after bone marrow transplantation was 7-9 years (range 3-2 to 11.4), and age at the most recent evalua- 
14.6) and who did not receive growth hormone (GH) treatment or other growth promoting agents, was evaluated. Median follow up period after bone marrow transplantation was 7-9 years (range 3-2 to 11.4) , and age at the most recent evaluation 18-1 years (range 15-6 to 24.5). Height values were expressed in standard deviation score (SDS) from the mean of the normal population. Height at bone marrow transplantation was compared with final height as well as with parental genetic height. Patients were divided into three groups: severe aplastic anaemia (SAA): three patients given no radiotherapy; leukaemia-total body irradiation (TBI): 14 patients with acute or chronic leukaemia conditioned with chemotherapy and TBI; leukaemia-TBI with previous cranial radiation therapy ( Impaired growth has been observed in children after bone marrow transplantation, and is probably associated with the radiotherapy and chemotherapy given.' Several studies have considered growth and growth rate in children after bone marrow transplantation26 but the follow up was short and the final height of these patients is not known. In a period of expanding use of recombinant human growth hormone (hGH) treatment in this group of patients,78 it is important to determine the spontaneous growth and final adult height of these children.
In this study we evaluated the final height achieved by patients who had bone marrow transplantation for haematological diseases during childhood and had never been treated with growth hormone preparations. No irradiation and TBI. Three had a six had a total dose of 8 three doses, and the rer TBI given in six doses three consecutive days).
Methods
ALL-TBI with pret therapy group (CRT) -: median age 9 9 years (I ALL who had cranial ra of their first line treE children received 18 G3 ing six patients received also received cycloph (single dose in one r divided doses in two an( tively) before bone mar Graft-versus-host dis laxis consisted either of in combination with GVHD was observed in These differences in height SDS values within the subgroups TBI and CRT were examined using the Student t test as well. -.3
Final height after bone marrow transplantation treatment included cyclophosph mg/kg and fractionated TBI (3-Height at the time of transplant N (-2-66 SDS), weight 36&0 kg. i prophylaxis treatment after trai included cyclosporin A for one cortisone for two months. Pub spontaneously at age 15 (three ye; transplant), and menarche appearc (her mother had menarche at ag particularly short stature at the transplant and the positive chang SDS observed in this patient at probably due to a constitutionc growth and puberty which would present whether or not she had rect marrow transplant.
Despite the general trend of height SDS found after bone ma plantation, only one patient preser considered to be a pathological that is, below -2. This subject was group and was exposed to 18 Gy Gy x 3 fractions of TBI.
Height The increasing number of long term surnted what is vivors after bone marrow transplantation has SDS value, focused attention on the additional effect of in the CRT this procedure on growth.1-8 Most children CRT and 3 who undergo allogeneic bone marrow transplantation have already been given combinaf bone mar-tion chemotherapy as first or second line antly higher treatment for leukaemia, and some of them 'H (t test; have also been exposed to cranial radiotherapy. mean final The impaired growth seen in children who er than the underwent bone marrow transplantation is . Analysing usually observed in those who received irradiairately, final tion therapy, and is probably due to a variety of than cMPH factors such as lesions to the bone epiphyses 022).
and hormone deficiencies (growth hormone, =0-01) was sex hormones, thyroid hormones).
[ntation and
Most studies dealing with the growth of nalysing the patients with haematological disorders who ). This was underwent bone marrow transplantation observed in report only limited data for the first few years after transplantation.'1-6 As bone marrow of chronic transplantation in childhood has been nt of height employed only during the last two decades, ie change in data on final adult height achieved by these transplanta-patients are scanty.8 16 Furthermore, some id in the 16 children with a reduced growth rate after trans-)nic GVHD plantation are treated with hGH in the absence ean value of of full knowledge of what the spontaneous final height would have been. '7-19 In this study we analyse the final height achieved by a relatively homogeneous group of patients with haematological diseases only (patients with solid tumours were excluded from the study group), who underwent allogeneic bone marrow transplantation during childhood. The final height of these patients was found to be lower than the predicted final height, based on both height SDS at the time of transplantation and genetic parental height (fig 1) . The greatest loss in height was observed in the irradiated groups, and in particular in patients who received prior CRT In the long term, chronic GVHD seems not to have any deleterious effect on the final height of these patients (p=0 16) . This is in disagreement with some reports in which chronic GVHD was found to be one of the factors causing short term growth impairment.1 3 This suggests that the period of chronic GVHD (the disease itself and its treatment) might be associated with growth impairment, and that a catch up in growth will follow after healing.
Davis et al have recently suggested that the impaired growth observed in surviving children with ALL is likely due to a disturbance of pubertal growth in combination with a direct toxic effect of chemotherapy on the cartilage growth plate, leading to skeletal disproportion. 14 On the other hand, it appears from our data that the younger these children are at the time of transplantation, the more profound will be the loss in height SDS (fig 3) . This means that the loss in height is a constant and continuous process, even during prepuberty.
The effect of the timing of puberty (spontaneous or induced by replacement sex hormone therapy) does not seem to play a role in the change in height SDS observed in our cohort of patients. In fact Dickerman et a!20 showed that the timing of the start of treatment with sex hormone in patients with isolated gonadotropin deficiency does not influence final height values.
In conclusion, growth impairment in children given bone marrow transplants for haematological diseases is due to a variety of factors such as chemotherapy/radiotherapy and immunosuppressive treatment, and therefore to damage to the cartilage growth plate and, to some extent, hormone insufficiency. Since in our study most patients who underwent bone marrow transplantation during childhood spontaneously reached final heights that were lower than expected but within the normal range for the healthy population, and since a possible interaction of GH with residual leukaemic cells cannot be excluded,21 concern should be raised about the use of hGH in this group of children. We therefore recommend that only children with severe height loss after bone marrow transplantation, identified by frequent clinical evaluations, should be considered for laborious pituitary-hypothalamic function tests. The decision to start hGH treatment should be made very carefully. For the moment, none of our transplanted children has needed hGH treatment.
